Learn about the act and its potential influence on the global clinical trial market
Exploring the new Medical Research Act
In our video series, we explore how the Medical Research Act is reshaping Germany’s clinical trial landscape, aligning with EU regulations while addressing inefficiencies in the authorization process. We discuss its potential to strengthen Germany’s position in key therapeutic areas like oncology and cardiovascular research, its influence on broader EU policies, and how streamlined contracting could accelerate patient recruitment.
In partnership with the vfa the Association of Research-Based Pharmaceutical Companies, we examine whether this act is a game-changer or just the first step toward making Germany a leader in clinical research once again, joined by guest speaker Thorsten Ruppert, Senior Manager Research, Development and Innovation from the vfa.
About the Medical Research Act
The Medical Research Act (Medizinforschungsgesetz, MFG), which came into force on 30 October 2024, is designed to enhance Germany’s appeal as a hub for pharmaceutical research and production. The Act seeks to achieve this by streamlining and expediting the evaluation process for clinical trials, offering incentives for medical research conducted within the country, and establishing a framework for promoting clinical trials, ensuring ethical standards, and improving data management and patient protection. These measures aim to foster innovation, attract investment, and strengthen Germany’s position as a leading player in the global pharmaceutical industry.
For more information, see the official overview here: BfArM – Medical Research Act